Indicator Explainer
HCV RNA
Qualitative or quantitative marker of active hepatitis C infection.
This page explains what the indicator is and how results are interpreted in general terms. Reference ranges depend on the laboratory, the method, and your own situation — no single “normal value” applies to everyone. This page is health information, not a diagnosis. For symptoms, treatment, or urgent concerns, contact a healthcare professional.
When it is tested
Used to confirm active infection after antibody reactivity and to quantify baseline viral load before antiviral therapy; also used during and after treatment to assess response.
Reading results
An antibody-positive, RNA-negative result reflects resolved or cleared infection rather than assay failure, but timing of testing matters during early infection. Quantitative values are platform-specific; sustained-virologic-response definitions belong to clinical protocols, not the laboratory report alone.
Questions to ask a professional
- Is this ordering qualitative or quantitative?
- When should the post-treatment confirmatory RNA test be scheduled?
References
- A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. — International journal of epidemiology, 1998 (PMID )
- Hepatitis C Virus and Hepatitis B Virus Co-Infection. — Viruses, 2020 (PMID doi: 10.3390/v12070741)
- Cost-effectiveness of opportunistic age-based hepatitis C screening using pooled HCV RNA testing in Galicia, Spain. — Rev Esp Enferm Dig, 2026-10-08 (PMID 42847887; literature)
- Optimizing the HCV Care Continuum in Primary Care: Opportunistic Screening With Point-Of-Care RNA Testing and Immediate Linkage-To-Care in Rio de Janeiro, Brazil. — J Viral Hepat, 2026-10-01 (PMID 42779227; literature)
- Development of a Machine Learning Model to Predict Short Duration HCV Treatment Response. — J Viral Hepat, 2026-10-01 (PMID 42745531; literature)
- Microelimination of hepatitis C in dialysis units: results from the Brazilian Registry for the elimination of HCV. — J Bras Nefrol, 2026-10-01 (PMID 42743380; literature)
- Five Years of HCV Dried Blood Spot Testing in At-Risk Populations and the Impact of Reduced Sensitivity on Missed Diagnoses. — Liver Int, 2026-10-01 (PMID 42661472; literature)
- Short-course prophylaxis with the Toronto HCV protocol for recipients of non-liver solid organ transplants from donors with hepatitis C viraemia: a retrospective, matched cohort study. — Lancet Gastroenterol Hepatol, 2026-09-29 (PMID 42810376; literature)
- A novel decentralized rapid test for detection of HCV antigens using smart polymer technology: a prospective multinational study. — J Infect Dis, 2026-09-17 (PMID 42752597; literature)
- Temporal changes in the prevalence of active HCV infection among people at risk of social exclusion in Seville. — Rev Esp Enferm Dig, 2026-09-09 (PMID 42714119; literature)
- The diagnostic gap in hepatitis C confirmation and the predictive value of the anti-HCV signal-to-cutoff ratio: a real-world study. — Indian J Med Microbiol, 2026-10-15 (PMID 42880411; literature)
- Clinical Performance of the Elecsys HCV Duo Immunoassay Compared with a Standard-of-Care Algorithm Using Alinity Anti-HCV Screening and HCV RNA Confirmation. — Diagnostics (Basel), 2026-10-07 (PMID 42882394; literature)
- Evaluating hepatitis C viremia and antiviral treatment barriers in hemodialysis patients in the post-HCV elimination era: Experience from Ain Shams University Hospitals. — Egypt J Immunol, 2026-10-01 (PMID 42873198; literature)
- Diagnostic gaps in HCV RNA testing in the era of elimination: a single-center study. — J Infect Dev Ctries, 2026-09-30 (PMID 42858351; literature)